Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)’s share price traded down 1.1% during trading on Tuesday . The stock traded as low as $12.35 and last traded at $12.35, with a volume of 329,103 shares. The stock had previously closed at $12.49.

Several equities analysts recently commented on the company. Piper Jaffray Cos. set a $16.00 target price on Vanda Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 18th. Zacks Investment Research upgraded Vanda Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $14.00 price objective for the company in a report on Tuesday, August 2nd. Brean Capital set a $20.00 price objective on Vanda Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, July 28th. Finally, Jefferies Group reiterated a “buy” rating on shares of Vanda Pharmaceuticals in a report on Friday, June 10th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Vanda Pharmaceuticals currently has an average rating of “Buy” and an average target price of $16.83.

The company’s market capitalization is $530.23 million. The firm’s 50 day moving average price is $11.82 and its 200-day moving average price is $9.76.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, July 27th. The biopharmaceutical company reported ($0.11) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.12. The company earned $36.02 million during the quarter, compared to the consensus estimate of $36.03 million. Vanda Pharmaceuticals’s revenue for the quarter was up 30.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.13) earnings per share. On average, equities research analysts expect that Vanda Pharmaceuticals Inc. will post ($0.61) earnings per share for the current year.

A hedge fund recently raised its stake in Vanda Pharmaceuticals stock. Schwab Charles Investment Management Inc. increased its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 260.3% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 268,633 shares of the biopharmaceutical company’s stock after buying an additional 194,080 shares during the period. Schwab Charles Investment Management Inc. owned 0.63% of Vanda Pharmaceuticals worth $2,501,000 as of its most recent filing with the SEC.

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.